HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Gracell Biotechnologies Inc (GRCL.US) - May Fail to Solve the Real Pain Points in CAR-T Field

Pre-IPO InSilico Medicine - AI Pharmaceutical Is Immature; Valuation Expansion Relies on Imagination

Pre-IPO WuXi XDC - The Beautiful Story and the Truth Behind

Wuxi Biologics (2269.HK) - Investor Day Brings New Surprises

Wuxi Biologics (2269.HK) - Some New Business Updates and the Outlook

WuXi AppTec (2359.HK/603259.CH) 2023Q1 - The Signals Behind the Plunge in Stock Price

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

<ul>
<li>Investors appear to have lost faith in China healthcare following a plunge in CXO shares.But seeing the decline in CXO orders as indicator of industry's prosperity is a lagging view.</li>
<li>The logic of CXO is tied to biotech on the one hand and to overseas relationships on the other. But Biotech remains the cornerstone of the overall logical chain. </li>
<li>According to the primary market situation, we’re not optimistic about CXO's domestic business to achieve a significant recovery next year, but the overseas recovery/financing situation may improve a bit faster.</li>
</ul>


Investors appear to have lost faith in China healthcare following a plunge in CXO shares.But seeing the decline in CXO orders as indicator of industry's prosperity is a lagging view.
The logic of CXO is tied to biotech on the one hand and to overseas relationships on the other. But Biotech remains the cornerstone of the overall logical chain. 
According to the primary market situation, we’re not optimistic about CXO's domestic business to achieve a significant recovery next year, but the overseas recovery/financing situation may improve a bit faster.


China CXO Has Reached a Crossroads - Time to Reconsider